TY - JOUR
T1 - Practical considerations for the use of SGLT-2 inhibitors in the Asia–Pacific countries—An expert consensus statement
AU - Liew, Adrian
AU - Lydia, Aida
AU - Matawaran, Bien J.
AU - Susantitaphong, Paweena
AU - Tran, Huong Thi Bich
AU - Lim, Lee Ling
N1 - Publisher Copyright:
© 2023 Asian Pacific Society of Nephrology.
PY - 2023/8
Y1 - 2023/8
N2 - Recent clinical studies have demonstrated the effectiveness of SGLT-2 inhibitors in reducing the risks of cardiovascular and renal events in both patients with and without type 2 diabetes mellitus. Consequently, many international guidelines have begun advocating for the use of SGLT-2 inhibitors for the purpose of organ protection rather than as simply a glucose-lowering agent. However, despite the consistent clinical benefits and available strong guideline recommendations, the utilization of SGLT-2 inhibitors have been unexpectedly low in many countries, a trend which is much more noticeable in low resource settings. Unfamiliarity with the recent focus in their organ protective role and clinical indications; concerns with potential adverse effects of SGLT-2 inhibitors, including acute kidney injury, genitourinary infections, euglycemic ketoacidosis; and their safety profile in elderly populations have been identified as deterring factors to their more widespread use. This review serves as a practical guide to clinicians managing patients who could benefit from SGLT-2 inhibitors treatment and instill greater confidence in the initiation of these drugs, with the aim of optimizing their utilization rates in high-risk populations.
AB - Recent clinical studies have demonstrated the effectiveness of SGLT-2 inhibitors in reducing the risks of cardiovascular and renal events in both patients with and without type 2 diabetes mellitus. Consequently, many international guidelines have begun advocating for the use of SGLT-2 inhibitors for the purpose of organ protection rather than as simply a glucose-lowering agent. However, despite the consistent clinical benefits and available strong guideline recommendations, the utilization of SGLT-2 inhibitors have been unexpectedly low in many countries, a trend which is much more noticeable in low resource settings. Unfamiliarity with the recent focus in their organ protective role and clinical indications; concerns with potential adverse effects of SGLT-2 inhibitors, including acute kidney injury, genitourinary infections, euglycemic ketoacidosis; and their safety profile in elderly populations have been identified as deterring factors to their more widespread use. This review serves as a practical guide to clinicians managing patients who could benefit from SGLT-2 inhibitors treatment and instill greater confidence in the initiation of these drugs, with the aim of optimizing their utilization rates in high-risk populations.
KW - acute kidney injury
KW - chronic kidney disease
KW - ketosis
KW - sodium-glucose transporter 2 inhibitors
KW - urinary tract infections
UR - http://www.scopus.com/inward/record.url?scp=85158094986&partnerID=8YFLogxK
U2 - 10.1111/nep.14167
DO - 10.1111/nep.14167
M3 - Review article
AN - SCOPUS:85158094986
SN - 1320-5358
VL - 28
SP - 415
EP - 424
JO - Nephrology
JF - Nephrology
IS - 8
ER -